アクセス数 : ?
ダウンロード数 : ?
ID 83940
著者
タカハシ, マサアキ Department of Pharmacy National Hospital Organization Nagoya Medical Center|Clinical Research Center, National Hospital Organization Nagoya Medical Center
ヒラノ, アツシ Department of Pharmacy National Hospital Organization Nagoya Medical Center|Clinical Research Center, National Hospital Organization Nagoya Medical Center
オオクボ, ナミ Department of Pharmacy National Hospital Organization Nagoya Medical Center
キノシタ, エリ Department of Pharmacy National Hospital Organization Nagoya Medical Center
ノムラ, トシハル Department of Pharmacy National Hospital Organization Nagoya Medical Center
カネダ, ツグヒロ College of Pharmacy, Kinjo Gakuin University
キーワード
maraviroc
CCR5 antagonist
HIV-1
LC-MS
therapeutic drug monitoring
資料タイプ
学術雑誌論文
抄録
Maraviroc is an orally available antagonist of the CCR5 chemokine receptor,
which acts as a human immunodeficiency virus type 1 (HIV-1) coreceptor. Binding of maraviroc
to this receptor blocks HIV-1 attachment to the coreceptor and prevents HIV-1
from entering host cells.Maraviroc does not require intracellular processing to exert
this activity. Drug interaction studies have shown changes in maraviroc exposure when
given with other anti-HIV medications, and thus quantification of maraviroc in human
plasma is important to manage drug interactions and to evaluate the relationship between
plasma concentrations and treatment response. We developed a conventional LCMS
method for determining plasma maraviroc concentrations, validated by estimating
precision and accuracy for inter- and intraday analysis in the concentration range of
0.011-2.188g/ml. The calibration curve was linear within this range. The average accuracy
ranged from 92.7% to 99.7%, while the relative standard deviations of both interand
intraday assays were less than 7.1%. Recovery of maraviroc exceeded 86.7%. Our LCMS
method provides a conventional, accurate and precise way to determine the maraviroc
concentration in human plasma. This method enables dose adjustment based on monitoring
plasma maraviroc concentrations and permits management of drug interactions
and toxicity.
掲載誌名
The journal of medical investigation : JMI
ISSN
13431420
cat書誌ID
AA11166929
57
3-4
開始ページ
245
終了ページ
250
並び順
245
発行日
2010-08
備考
The journal of medical investigation : http://medical.med.tokushima-u.ac.jp/jmi/index.html
フルテキストファイル
言語
eng